

- Triiodothyronine (T₃)
 characteristics of, 2286f
 free, 2286, 2288
 half-life of, 400e-2
 laboratory evaluation of, 2286t, 2288, 2763t
 receptor binding of, 2287, 2287f
 in sick euthyroid syndrome, 2299
 structure of, 2283f
 in subacute thyroiditis, 2298–2299, 2298f
 total, 2288
 transport and metabolism of, 2285–2286
- Trilostane, 2273
- TRIM5- α protein, 1217
- Trimethoprim
 action of, 64e-2, 332e-8, 641, 931t, 932
 adverse effects of, 64e-2, 246e-4t, 297, 310, 321, 647
 drug interactions of, 246e-4t
 indications for, 246e-4t
 for PCP, 1361t
 resistance to, 931t, 934
- Trimethoprim-polymyxin, 199
- Trimethoprim-sulfamethoxazole (TMP-SMZ)
 for *Acinetobacter* infections, 1037t
 action of, 943
 adverse effects of, 867t, 938t, 943, 1361, 1361t
 cholestatic hepatitis, 284
 in G6PD deficiency, 656t
 hepatotoxicity, 2029–2030
 in HIV infection, 1259, 1260
 neutropenia, 417
 thrombocytopenia, 727t
 vasculitis, 2218t
 for *B. cepacia* infections, 1045t
 for bite-wound infections, 167e-2, 167e-3t
 for blastocystosis, 1409
 for *Brucella* spp. infections, 194e-4
 for *C. belli* infections, 1407
 for chronic granulomatous disease, 423
 for *Cyclospora* infections, 1408
 for cystitis, 866, 867t
 for donovanosis, 198e-2t
 drug interactions of, 939t
 for enteric fever, 1052t
 for glanders, 1045t
 for granulomatosis with polyangiitis, 2185
 indications for, 941t, 943
 for *L. monocytogenes* infections, 983
 for *Legionella* infections, 1020t
 for melioidosis, 1045t
 for MRSA infections, 345, 962t
 for *Nocardia* infections, 1087
 for nontyphoidal *Salmonella* infections, 1054t
 for osteomyelitis, 840t, 841t
 for otitis media, 230
 for paracoccidioidomycosis, 1354t
 for PCP, 1361, 1361t
 for PCP in HIV infection, 1251t, 1253–1254, 1830
 for pertussis, 1024, 1024t
 for plague treatment, 261e-5
 prophylactic
 in chronic neutropenia, 423
 for cystitis, 889
 in HIV infection, 1251t
 for PCP, 1251t, 1362t
 for peritonitis, 847
 for plague, 1075t
 for toxoplasmosis, 1251t, 1404
 in transplant recipient, 139e-4t, 921, 925–926, 925t
 for pyelonephritis, 867
 resistance to, 943
E. coli, 1029
 in *E. coli*, 862
 mechanisms of, 934
 rates of, 941t
 for *S. maltophilia* infections, 1045t
 for staphylococcal soft tissue infections, 962t
 for vasculitis, 2182
 for Whipple's disease, 1093–1094, 1945
- Trimethylaminuria (fish odor syndrome), 96e-6
- Trimetrexate, 246e-3t
- Trinucleotide repeat disorders, 434, 440, 440t
- Triose phosphate isomerase deficiency, 654t
- Triple A syndrome, 2324t
- Triple-negative breast cancer, 526
- Triptans, 473e-13t, 2591, 2592t
- Trismus (lockjaw), 985, 2647
- Trisomy, 83e-4
- Trisomy 6, 83e-4
- Trisomy 8, 135e-6
- Trisomy 13, 83e-4, 1654
- Trisomy 18, 83e-4, 1654
- Trisomy 21. *See* Down's syndrome (trisomy 21)
- Tritium exposure, 263e-3t, 263e-6t, 263e-7
- TrkB* gene, 415e-4t
- TRK* gene mutations, 101e-3t, 2304, 2305t
- Trochanteric bursitis, 2222, 2222f, 2247
- Trochlear nerve, 2537
 injuries of, 457e-2
 palsy, 209
- Troglitazone, 96e-6, 2025, 2415
- Tropheryma whipplei*. *See also* Whipple's disease
 asymptomatic colonization of, 1092
 characteristics of, 840, 1091, 1945
 isolated infection, 1093
- Trophoblast stem cells, 453, 453t
- Trophozoites, *Plasmodium*, 1369
- Tropical pulmonary eosinophilia, 422, 1420
- Tropical spastic paraparesis. *See* Human T-cell lymphotropic virus-1 (HTLV-1) infections, myelopathy
- Tropical splenomegaly, 1374–1375
- Tropical sprue, 1942
 clinical features of, 269, 1942
 clinical pattern of, 1943
 cobalamin deficiency in, 645
 diagnosis of, 1943
 etiology of, 1943
 small-intestinal mucosal biopsies in, 1939, 1940t, 1941f, 1942
 treatment of, 1943
- Tropisetron, 566
- Tropomyosin, 265e-6, 1556f
- Troponins
 in cardiac contraction, 265e-4–5, 265e-5f
 in cardiac trauma, 289e-3
 in chest pain evaluation, 101
 in chronic kidney disease, 1817
 in heart failure, 1505
 in myocardial infarction, 1594, 1596t, 1600–1601, 1601f
 reference values for, 2763t
- Trousseau's sign, 315
- Trousseau's syndrome, 511, 613
- TRPM6* gene mutations, 332e-8
- TRP proteins, 212
- TRPs (transient receptor potentials), 444e-9
- Trubanam virus, 1306t, 1313
- True bug bites, 2750
- True hermaphroditism. *See* Ovotesticular disorders of sexual development
- True-negative tests, 21, 22
- True neurogenic thoracic outlet syndrome (TOS), 122
- True-positive tests, 21, 22
- Trust, between patient and health care provider, 16e-4–5, 16e-6–7
- Trypanosoma* spp.
 entry into host, 145e-1
T. brucei gambiense/rhodesiense, 245e-4t, 245e-6t, 908t, 1396, 1396t. *See also* Sleeping sickness (human African trypanosomiasis)
T. cruzi, 245e-2, 245e-4t, 245e-6t, 1394. *See also* Chagas disease
- Trypanothione reductase, 246e-7
- L-Tryptophan
 contamination of, 14e-3, 376, 423, 462e-20, 2155, 2199
 drug interactions of, 2711t
 overdose/poisoning with, 473e-13t
 Tryptophan hydroxylase, 372e-24t
 Tryptophan metabolism disorders, 434e-2t
 Tryptophanuria, 434e-2t
TSC1/2 gene mutations, 101e-6t, 465e-1, 465e-2t, 1854
- T-scores, 2488, 2493, 2493f
- Tsetse flies, in sleeping sickness, 1396
- TSH. *See* Thyroid-stimulating hormone (TSH)
- TSI (thyroid-stimulating immunoglobulins), 2288, 2294
- TSLP (thymic stromal lymphopoietin), in asthma, 1672
- T-SPOT TB assay, 1115
- TSS. *See* Toxic shock syndrome (TSS)
- TTF-1. *See* Thyroid transcription factor-1 (TTF-1)
- TTF-2, 2283, 2284t
- TTKG (transtubular K⁺ concentration gradient), 64e-7, 307, 311, 311f
- TTN* gene mutations, 1564
- TTP. *See* Thrombotic thrombocytopenic purpura (TTP)
- TTR. *See* Transthyretin (TTR)
- Tubal pregnancy. *See* Ectopic pregnancy
- Tuberculin skin test (TST). *See* Purified protein derivative (PPD)/tuberculin skin test (TST)
- Tuberculoma, 1111
- Tuberculosis (TB), 1102
 anemia in, 630
 AV conduction block in, 1471t
 bronchiectasis in, 1695
 in cancer patient, 484t, 485, 486t
 as cause of fever of unknown origin, 138, 141
 in children, 1108, 1108f
 as chronic disease, 13–14
 diagnosis of
 culture, 1113
 drug susceptibility testing, 1113–1114
 genomics in, 769t
 imaging, 308e-3f, 1108f, 1109f, 1114
 invasive procedures, 1114
 limitations of, 770
 microscopy, 1113
 nucleic acid amplification, 150e-8, 1113
 serologic tests, 1114
 sputum analysis, 1114
 tuberculin skin testing, 1107, 1114
 epidemiology of, 12–13, 205e-1, 1103–1105, 1104f
 etiology of. *See* *Mycobacterium tuberculosis*
 extensively drug-resistant, 13, 1116t, 1119, 1119t
 extrapulmonary
 adrenal, 1112
 aortic aneurysm, 1638
 congenital, 1112
 gastrointestinal, 287, 1111
 genital, 335
 genitourinary, 1110, 1110f
 in HIV infection, 1112–1113
 lymphadenitis, 408, 1109, 1109f
 lymphedema, 1654
 mastitis, 1112
 meningitis, 488, 766t, 775, 907t, 1111
 military, 138, 1108f, 1112, 1119
 myocarditis, 992
 ocular manifestations, 1112
 oral manifestations, 237, 238t, 241
 otitis, 1112
 pericardial, 1574, 1577
 pericarditis, 1111–1112
 pleural, 1109–1110
 skin manifestations, 366, 367, 829, 1112
 spinal/skeletal
 vs. *Brucella* infection, 194e-2, 194e-2t
 clinical features of, 836, 1110–1111
 diagnosis of, 138
 MRI, 441e-2f
 osteomyelitis, 836
 Pott's disease, 836, 1110, 1111f
 treatment of, 1119–1120
 tuberculoma, 1111
 upper airway, 234, 1110
 global burden of, 12–13, 205e-1, 1103–1105, 1104f
 in HIV infection
 antiretroviral therapy and, 205e-1, 1112–1113
 clinical features of, 1112–1113, 1254